Workflow
Cocrystal(COCP)
icon
Search documents
Cocrystal Pharma (COCP) Investor Presentation - Slideshow
2022-11-22 16:43
C@CRYSTAL Potent antivirals to combat some of the most serious diseases facing humanity November 2022 Nasdaq: COCP www.cocrystalpharma.com 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our programs; the development pipeline; our technology platform's ability to produce viable drug candidates ...
Cocrystal(COCP) - 2022 Q3 - Quarterly Report
2022-11-13 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSIT ...
Cocrystal Pharma (COCP) Investor Presentation - Slideshow
2022-11-07 17:08
C@CRYSTAL Potent antivirals to combat some of the most serious diseases facing humanity October 2022 Nasdaq: COCP www.cocrystalpharma.com 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our programs; the development pipeline; our technology platform's ability to produce viable drug candidates a ...
Cocrystal Pharma (COCP) Presents At Dawson James Securities 2022 Small Cap Growth Conference - Slideshow
2022-10-24 13:36
C@CRYSTAL Potent antivirals to combat some of the most serious diseases facing humanity Dawson James Securities 2022 Small Cap Growth Conference October 12, 2022 Nasdaq: COCP www.cocrystalpharma.com 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our programs; the development pipeline; our tech ...
Cocrystal Pharma (COCP) Investor Presentation - Slideshow
2022-08-17 21:19
Pipeline Highlights - Cocrystal Pharma is advancing COVID-19 and influenza programs, targeting large global markets for acute and pandemic viral diseases[7] - Planned Phase 1 trials in 2022 for COVID-19 oral protease inhibitor and CDI-45205 lead molecule[7, 8] - Influenza A CC-42344 (oral administration) Phase 1 results are expected in 2022, with a Phase 2a study expected to begin in 2023[7] - Preclinical lead selection for the Norovirus Gastroenteritis program is planned for 2022-2023[8] Collaboration and Technology - Merck collaboration for influenza A/B therapeutic validates Cocrystal's drug discovery platform technology, with potential for up to $156 million in milestone payments plus royalties[7, 28] - The company's proprietary drug discovery platform technology aims for viable drug candidates at reduced development timelines and costs[9, 11] Financial Status - As of June 30, 2022, Cocrystal Pharma had approximately $51 million in cash and equivalents[45] - The company has a clean balance sheet with no preferred shares or debt, and cash is sufficient to fund planned operations[7, 45] - The company's market capitalization is approximately $47 million[44] Market and Disease Overview - The global influenza therapeutics market is projected to reach $95 billion by 2027, growing at a 48% CAGR between 2021 and 2027[23] - Norovirus is responsible for approximately 685 million infections annually worldwide, costing an estimated $60 billion annually[31] - An estimated 58 million people worldwide have chronic hepatitis C virus infection, with about 15 million new infections occurring per year[36]
Cocrystal(COCP) - 2022 Q2 - Quarterly Report
2022-08-14 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION R ...
Cocrystal(COCP) - 2022 Q1 - Quarterly Report
2022-05-10 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION ...
Cocrystal Pharma (COCP) Investor Presentation -Slideshow
2022-03-22 18:43
CQCRYSTAL Potent antivirals to combat some of the most serious diseases facing humanity March 2022 Nasdaq: COCP www.cocrystalpharma.com 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our programs; the development pipeline; our technology platform's ability to produce viable drug candidates at ...
Cocrystal(COCP) - 2021 Q4 - Annual Report
2022-03-22 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share COCP The Nasdaq Stock Market LLC (The Nasdaq Capital Market) Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 OR ☐ TRANSITION RE ...
Cocrystal Pharma (COCP) Investor Presentation - Slideshow
2022-03-12 16:03
C@CRYSTAL Potent antivirals to combat some of the most serious diseases facing humanity February 2022 Nasdaq: COCP www.cocrystalpharma.com 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our programs; the development pipeline; our technology platform's ability to produce viable drug candidates ...